Financing will further accelerate the already successful early commercial rollout of VitaSmart™ HOPE System

融资将进一步加速VitaSmart™ HOPE系统已经取得成功的早期商业化推广

Company also advancing an active organ viability assessment tool designed to raise industry standards with a validated biomarker that gives transplant centers the data to save more organs and lives

该公司还在推进一种主动的器官活力评估工具，该工具采用经过验证的生物标志物，为移植中心提供数据支持，以挽救更多器官和生命，从而提升行业标准。

Funds fuel Bridge to Life's multi-organ product pipeline and reinforce its market leadership

资金助力Bridge to Life的多器官产品管线，并巩固其市场领先地位

DULUTH, Ga.

佐治亚州杜鲁斯

,

，

Aug. 12, 2026

2026年8月12日

/PRNewswire/ -- Bridge to Life™ Ltd., a market leader in organ preservation solutions and perfusion technologies, today announced the successful completion of a $110 million Series C and debt financing. The equity financing was led by new investor Soleus Capital, along with Lauxera Capital Partners and participation by Bridge to Life directors, officers, and employees; the debt financing was provided by Soleus Capital Credit Opportunities Fund.

/美通社/ -- 器官保存解决方案和灌注技术市场领导者Bridge to Life™ Ltd.今天宣布成功完成1.1亿美元的C轮股权融资及债务融资。此次股权融资由新投资者Soleus Capital领投，Lauxera Capital Partners跟投，Bridge to Life的董事、高管和员工也参与了投资；债务融资由Soleus Capital Credit Opportunities Fund提供。

Proceeds will fuel the VitaSmart™ launch by expanding the field team and providing the working capital to reach every U.S. transplant center. The remaining funds will advance Bridge to Life's new product pipeline, including a proprietary viability assessment tool, broadening its organ preservation portfolio, and scaling global operations.

所得款项将用于推动 VitaSmart™ 的上市，包括扩充现场团队并提供营运资金，以覆盖美国所有移植中心。剩余资金将用于推进 Bridge to Life 的新产品管线，包括一款专有的活力评估工具，拓展其器官保存产品组合，并扩大全球运营规模。

Proceeds were also used to refinance the Company's credit facility with Perceptive Credit Funds, thereby significantly reducing the Company's outstanding leverage and lowering its interest rate, as Bridge to Life has evolved from early development stage to a fully commercial organization..

所得款项亦用于再融资公司与Perceptive Credit Funds的信贷安排，从而显著降低公司的未偿杠杆水平并下调其利率，因为Bridge to Life已从早期开发阶段转型为一家完全商业化的组织。

Following its U.S. Food and Drug Administration (FDA) De Novo clearance in January 2026, the VitaSmart™ Hypothermic Oxygenated Perfusion (HOPE) System is the first and only hypothermic oxygenated perfusion system authorized by the FDA for use in liver transplantation.

继2026年1月获得美国食品药品监督管理局（FDA）的De Novo许可后，VitaSmart™低温氧合灌注（HOPE）系统成为首个且唯一获FDA批准用于肝移植的低温氧合灌注系统。

'Bridge to Life is committed to improving transplant medicine through science-based solutions that bring more organs to more patients,' said Don Webber, CEO and President of Bridge to Life™ Ltd. 'This financing marks an important milestone for Bridge to Life and reflects the confidence our investors have in our technology, team, and long-term growth strategy.

“Bridge to Life 致力于通过基于科学的解决方案，为更多患者提供更多器官，从而推动移植医学的进步，” Bridge to Life™ Ltd. 的首席执行官兼总裁 Don Webber 表示。“此次融资标志着 Bridge to Life 的一个重要里程碑，也反映了投资者对我们技术、团队以及长期增长战略的信心。”

The VitaSmart launch has outpaced our expectations, as leading academic centers are adopting it rapidly. This financing enables us to meet that demand while advancing a pipeline that expands beyond liver transplantation to other solid organ transplants.' Webber further commented, 'The Company would like to extend its appreciation for the financial support provided by Perceptive Credit Funds, through funding the Company's VitaSmart clinical development, FDA clearance and initial commercial launch.'.

VitaSmart 的上市速度超出了我们的预期，因为领先的学术中心正在迅速采用该产品。此次融资使我们能够满足这一需求，同时推进产品管线，将其应用范围从肝脏移植扩展到其他实体器官移植。”Webber 进一步评论道：“公司谨对 Perceptive Credit Funds 提供的财务支持表示衷心感谢，该支持资助了公司 VitaSmart 的临床开发、FDA 许可及初步商业发布。”

'We led this financing because Bridge to Life pairs an established preservation franchise with a newly FDA-cleared perfusion platform that is already rapidly being adopted in the field, and with a credible pipeline behind it — this is a combination we believe is unmatched in the transplant category,' said Ben Lund, Partner, Soleus Capital.

“我们领投此次融资，是因为Bridge to Life将成熟的器官保存业务与一款新近获得FDA许可的灌注平台相结合，该平台已在临床领域迅速得到采用，并且背后拥有可靠的研发管线——我们认为，这种组合在移植领域是无与伦比的。”Soleus Capital合伙人本·伦德表示。

'We are excited to partner with Lauxera with whom we share a deep understanding of this market and conviction in Bridge to Life's future potential.'.

“我们很高兴与 Lauxera 合作，双方对这一市场有着深刻的理解，并对 Bridge to Life 的未来潜力充满信心。”

'We have substantial experience investing in organ transplantation devices and we have seen firsthand how difficult it is to carry a preservation technology from clinical promise through to routine practice,' said Samuel Levy, Co-Founding Partner, Lauxera Capital Partners. 'Bridge to Life has done exactly that with a technology combining long-duration perfusions, class-leading ease of use, an accessible price point and outstanding clinical outcomes.

“我们在器官移植设备投资方面拥有丰富经验，并亲眼见证了将一项保存技术从临床前景转化为常规实践的难度之大，”Lauxera Capital Partners 的创始合伙人塞缪尔·莱维表示。“Bridge to Life 正是凭借一项集长时间灌注、业界领先的易用性、亲民的价格以及卓越的临床疗效于一体的技术，成功实现了这一目标。”

These characteristics will accelerate machine perfusion adoption saving lives and reducing costs for the healthcare system.'.

这些特点将加速机器灌注技术的采用，从而挽救生命并降低医疗系统的成本。

Creating a New Standard of Care in Perfusion

在灌注领域建立新的护理标准

Proceeds from this financing will primarily be used to scale the company's commercial and clinical field organizations, providing the infrastructure required to deliver VitaSmart™ to every U.S. transplant center seeking to modernize its organ preservation capabilities. In just six months, VitaSmart™ has rapidly become part of routine clinical practice as evidenced by:.

本次融资所得资金将主要用于扩大公司的商业和临床现场组织规模，为向每家寻求现代化器官保存能力的美国移植中心提供VitaSmart™所需的基础设施。在短短六个月内，VitaSmart™已迅速成为常规临床实践的一部分，证据如下：

Master service agreements with a rapidly growing number of leading academic transplant centers, organ procurement organizations, and several of the nation's highest-volume liver transplant programs, including first-time adopters of cold perfusion

与数量迅速增长的领先学术移植中心、器官获取组织以及全国多个最高量的肝移植项目（包括首次采用冷灌注技术的项目）签订主服务协议

Strong customer loyalty demonstrated through a remarkable cadence of repeat orders

通过频繁重复下单展现出的强大客户忠诚度

A robust pipeline of additional U.S. transplant centers in the process of adopting VitaSmart™

更多美国移植中心正在逐步采用 VitaSmart™，形成强劲的增长势头

With more than 100,000 U.S. patients currently awaiting life-saving transplants, there is a critical need to maximize the use of every available donor organ. The VitaSmart™ System directly addresses this acute shortage by expanding the pool of viable organs, helping to reduce waitlist times and save more lives..

目前，美国有超过10万名患者正在等待挽救生命的器官移植，因此亟需最大限度地利用每一个可用的捐赠器官。VitaSmart™系统通过扩大可用器官池，直接应对这一严峻短缺问题，有助于缩短等待名单时间并挽救更多生命。

Meeting the Unmet Need for Assessing Organ Viability

满足评估器官活力的未竟需求

Bridge to Life is advancing a first-in-class, science-based viability assessment tool designed to set a new industry standard in transplant medicine. It aims to address one of transplantation's most persistent challenges: currently, donated organs are accepted or declined based on a combination of visual assessment, donor characteristics, clinical judgment, and, during normothermic perfusion, surrogate measures such as lactate clearance and bile production.

Bridge to Life 正在推进一款首创的、基于科学的活力评估工具，旨在为移植医学树立新的行业标准。该工具旨在解决移植领域最持久的挑战之一：目前，捐赠器官的接受或拒绝是基于视觉评估、供体特征、临床判断以及在常温灌注期间的替代指标（如乳酸清除率和胆汁生成量）的综合考量。

Bridge to Life seeks to augment these traditional measures with a more definitive, science-based evaluation of organ viability. Objective decision support at the point of evaluation can give surgeons the confidence to accept marginal and extended-criteria grafts, reduce preventable organ non-use, and standardize acceptance practice across centers..

Bridge to Life 旨在通过更具决定性、基于科学的器官活力评估，来补充这些传统措施。在评估阶段提供客观的决策支持，能够增强外科医生接受边缘供体和扩展标准移植物（extended-criteria grafts）的信心，减少可预防的器官废弃，并统一各移植中心的接受实践标准。

The viability assessment tool is currently in development and under investigation, and it is not cleared for commercial sale at this time.

可行性评估工具目前正在开发和调查中，尚未获准进行商业销售。

Expanding Product Portfolio Beyond Liver

拓展肝脏以外的产品组合

The remaining capital will fund Bridge to Life's broader innovation pipeline, expanding its organ preservation and perfusion portfolio beyond liver transplantation into additional organ applications over the next three years. In addition, the company is actively developing next-generation closed systems to streamline transport, thereby supporting the expansion of Bridge to Life's global commercial footprint..

剩余资金将用于资助Bridge to Life更广泛的创新产品线，在未来三年内将其器官保存和灌注产品组合从肝脏移植扩展到其他器官应用。此外，公司正在积极开发下一代封闭系统以简化运输流程，从而支持Bridge to Life全球商业版图的扩张。

Advisors

顾问

UBS Investment Bank acted as exclusive financial advisor and placement agent to Bridge to Life in connection with the transaction. Morgan, Lewis & Bockius LLP acted as legal counsel for Bridge to Life in connection with the transaction.

瑞银投资银行在此次交易中担任Bridge to Life的独家财务顾问及配售代理。摩根·刘易斯与博克ius律师事务所在此次交易中担任Bridge to Life的法律顾问。

About Bridge to Life™ Ltd.

关于 Bridge to Life™ 有限公司

Bridge to Life™ Ltd. is a global leader in organ preservation and perfusion technology. Driven by a commitment to science-based innovation, the company empowers transplant teams with advanced tools that expand the donor pool, streamline clinical workflows, and improve patient outcomes worldwide. VitaSmart™ joins a preservation franchise anchored by Belzer UW.

Bridge to Life™ Ltd. 是全球器官保存和灌注技术领域的领导者。公司秉持以科学为基础的创新承诺，为移植团队提供先进工具，以扩大供体池、优化临床工作流程并改善全球患者的预后。VitaSmart™ 加入了以 Belzer UW 为核心的器官保存产品系列。

®

®

, widely regarded as the global gold standard in cold static preservation and the most extensively used cold flush solution in abdominal organ transplantation. Together, the portfolio gives Bridge to Life a differentiated position spanning both established preservation and next-generation machine perfusion..

，被广泛认为是冷静态保存领域的全球金标准，也是腹部器官移植中使用最广泛的冷冲洗液。该产品组合共同赋予了 Bridge to Life 公司独特的市场地位，涵盖传统保存技术与下一代机器灌注技术。

About Soleus Capital

关于Soleus Capital

Soleus Capital is an investment firm based in Greenwich, CT focused on the innovative areas of life sciences, including biopharmaceuticals, medical technologies, life sciences tools and diagnostics. With approximately $3.5 billion in total assets under management as of June 30, 2026, Soleus Capital invests across the healthcare lifecycle from developmental-stage through commercial, and partners with life science companies across the capital structure with hedge fund, private equity and structured credit vehicles..

Soleus Capital 是一家总部位于康涅狄格州格林威治的投资公司，专注于生命科学领域的创新板块，包括生物制药、医疗技术、生命科学工具及诊断。截至2026年6月30日，该公司管理总资产约35亿美元，投资覆盖医疗健康产业从开发阶段到商业化阶段的全生命周期，并通过对冲基金、私募股权和结构化信贷等载体，与生命科学公司在资本结构的不同层面开展合作。

About Lauxera Capital Partners

关于 Lauxera Capital Partners

Founded in 2020, Lauxera Capital Partners is an independent investment firm exclusively dedicated to Healthtech. Based in Paris and San Francisco, the firm is led by entrepreneurial company builders and seasoned investors. Lauxera manages more than $1 billion in assets and supports 14 portfolio companies as a hands-on operational and financial partner.

Lauxera Capital Partners 成立于2020年，是一家专注于健康科技领域的独立投资公司。公司总部位于巴黎和旧金山，由具有创业经验的企业构建者和资深投资者领导。Lauxera 管理资产规模超过10亿美元，作为深入参与的运营与财务合作伙伴，支持着14家投资组合公司。

Since its founding, Lauxera has championed investing for impact in pursuit of a more sustainable and effective healthcare system, tracking the positive impact of its portfolio companies on patients, providers and healthcare systems..

自成立之日起，Lauxera 便致力于通过影响力投资推动构建更可持续、更高效的医疗保健体系，并持续追踪其投资组合公司在患者、医疗服务提供方以及医疗保健系统方面产生的积极影响。

Product Development and Forward-Looking Statements

产品开发与前瞻性陈述

Pipeline programs described in this release are in development, are investigational, and are not cleared or approved by the U.S. Food and Drug Administration or any other regulatory authority. Nothing herein should be construed as a claim of safety or effectiveness for any use that has not received clearance or approval.

本新闻稿中所述的在研管线项目正处于开发阶段，属于研究性产品，尚未获得美国食品药品监督管理局或任何其他监管机构的许可或批准。本文任何内容均不应被解释为对任何尚未获得许可或批准的用途的安全性或有效性的声明。

Commercial and clinical figures cited in this release are preliminary and unaudited as of July 24, 2026..

本新闻稿中引用的商业和临床数据截至2026年7月24日为初步且未经审计的数据。

SOURCE Bridge to Life, Ltd.

来源：生命之桥有限公司

21

二十一

%

%

more press release views with

更多新闻稿浏览量，通过

Request a Demo

申请演示